Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the...
-
PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and genetics London, UK, 13 November 2025 — IMU Biosciences (or “the...
-
PRESS RELEASE IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies Consortium includes leading research institutions, NHS Trusts and...
-
IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer London, UK, 17 September 2024 –...
-
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin...